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Abstract: This study aims to evaluate the acute effects of an oscillat-
ing positive expiratory pressure device (flutter) on airways resistance in
patients with chronic obstructive pulmonary disease (COPD).
Randomized crossover study: 15 COPD outpatients from Asthma
Lab–Royal Brompton Hospital underwent spirometry, impulse oscil-
lometry (IOS) for respiratory resistance (R) and reactance (X), and
fraction exhaled nitric oxide (FeNO) measures.
Thirty minutes of flutter exercises: a ‘‘flutter-sham’’ procedure was
used as a control, and airway responses after a short-acting broncho-
dilator were also assessed.
Respiratory system resistance (R): in COPD patients an increase in
X5insp (0.21 to0.33 kPa/L/s) and Fres (24.95 to 26.16Hz) occurred
immediately after flutter exercises without bronchodilator. Following 20
min of rest, a decrease in the R5, DR5, R20, X5, and Ax was observed,
with R5, R20, and X5 values lower than baseline, with a moderate effect
size; there were no changes in FeNO levels or spirometry.
The use of flutter can decrease the respiratory system resistance and
reactance and expiratory flow limitation in stable COPD patients with
small amounts of secretions.
(Medicine 94(42):e1845)
Abbreviations: DR5 = R5insp-R5exp, Ax = reactance area, BMI =
body mass index, COPD = chronic obstructive pulmonary disease,aredi, MD, Anjana
and Omar S. Usmani, MD
Lung Disease, Insp = inspiratory, IOS = impulse oscillometry, kPa/
L/s = kilopascal/L/s, MEF = medium expiratory flow, R20 =
R20insp-R20exp, R20 = respiratory system resistance at 20Hz, R5
= respiratory system resistance at 5Hz, SaO2 = oxygen saturation,
X20 = reactance system reactance at 20Hz, X5 = reactance system
reactance at 5Hz.
INTRODUCTION
C hronic obstructive pulmonary disease (COPD) is charac-terized by persistent airflow limitation usually progressive
and associated with an enhanced chronic inflammatory
response in the airways to noxious particles or gases.1 Chronic
obstructive pulmonary disease patients exhibit pathological
changes in the small airways, where inflammation may cause
increased viscid mucus secretions that further narrow the airway
lumen and increase the resistance to airflow.2 These pathophy-
siological features contribute to clinical manifestations of dys-
pnea, sputum production, and exercise limitation.1
Physiotherapy is an integral part of the multidisciplinary
management of COPD patients and a recent Cochrane review
indicates that airway clearance techniques (ACT) are safe for
individuals with COPD and confer small beneficial effects on
some clinical outcomes such as a reduction in the need for
hospital admission and improvement in health-related quality of
life.3
The ACT can include the oscillating positive expiratory
pressure devices using the flutter valve that is a simple, small,
pipe-shaped device described by Lindemann in 1992.4 The
flutter creates a fluctuating positive expiratory pressure at the
mouth and intrathoracic oscillations within the respiratory tree
that mobilize airway secretions facilitating their clearance and
improving airflow within the airways.
The effects of flutter exercises on airways resistance are
not well characterized5–8 and impulse oscillometry (IOS) can
be a noninvasive, reliable, and easy-to-perform method to
assess respiratory system resistance.
Impulse oscillometry gives a functional assessment of
airways, particularly small airways, beyond that available from
conventional lung function tests,9,10 based on the concept that
the impedance of the respiratory system (Zrs) can be conceived
as a generalization of resistance since it embodies both the in-
phase (resistance-R) and out-of-phase (reactance-X) relation-
ships between the pressure and the flow. The comparison
between inspiratory and expiratory R and X may be used as
a marker of airflow limitation in patients with COPD10,11 andn used to assess central and distal airway
ons.9,11,12 Additionally, the removal of
e inflammation, and the fraction of
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exhaled nitric oxide (FeNO), a noninvasive breath biomarker of
airways inflammation, could be a helpful method to evaluate the
effects of CPT.13,14
The main objective was to determine the effect of 30 min
of breathing exercises with a flutter device on airways resistance
and small airways function assessed by IOS in patients with
COPD. The secondary objective was to investigate the effect of
the removal of secretions on airways inflammation.
MATERIAL AND METHODS
Design
It is a randomized, crossover, controlled study.
Subjects
Patients with COPD (n¼ 15), mean age 67.3 9.1 years,
body mass index (BMI) 24.9 4.3 kg/cm2, and smoking history
of 27.6 6.7 pack/years, attended the clinical laboratory for 4
study visits, from January to August, 2013. The severity of
COPD was stated according to the GOLD: I¼ 2 patients, II¼ 7
patients; III¼ 5 patients, and IV¼ 1 patient.1
Gastaldi et alWere excluded subjects with upper respiratory tract infec-
tion or treatment with antibiotics within 4 weeks prior the study;









1) Allocated to sham group (n= 8) 
 Received allocated intervention (n= 8) 
2) Allocated to flutter group (n= 8) 
 Received allocated intervention (n= 8) 
3) Allocated to flutter+bronchodilator 
group (n= 8) 
 Received allocated intervention (n= 8) 
Analysed immediately (n= 8) 
Analysed after 20 minutes (n= 8) 
 
♦ Excluded from analysis (give reasons) (n= 0) 
FIGURE 1. Flow diagram of patients.
2 | www.md-journal.compneumothorax. All subjects gave their written informed consent
and the study was approved by National Research Ethics
Service, United Kingdom (reference 13/LO/0339) and was
registered prospectively on the public website Clinicaltrials.gov
(reference NCT01832961).
Intervention
At visit 1, all patients underwent a medical history,
physical examination, and written informed consent was taken.
At each of the other 3 study visits, they undertook baseline tests
(FeNO, IOS, and spirometry), after tests (immediately after
intervention or control), and an additional IOS measure after 20
min of rest.
They performed the breathing exercises using a function-
ing flutter device (Varioraw SARL, Scandipharm Inc, Birming-
ham, AL), or with a flutter-sham (control) (visits 2 and 3). In
visit 4, patients were pretreated with short-acting bronchodilator
(salbutamol 400mg), and 1 h later, they performed the flutter
exercises (flutterþ bronchodilator) (Fig. 1), with an interval of
3 to 5 days (washout).
Additional assessments including the expectorated volume
Medicine  Volume 94, Number 42, October 2015of secretions, the subject’s oxygen saturation—SaO2 (Radical-
7, Masimo Corporation, Irvine, CA), and the number of spon-
taneous coughs were monitored.
ligibility (n= 21) 





   Not meeting inclusion criteria (n= 2) 
♦   Declined to participate (n= 0) 




sed (n= 15) 
1) Allocated to flutter group (n= 7) 
 Received allocated intervention (n= 7) 
2) Allocated to sham group (n= 7) 
Received allocated intervention (n= 7) 
3) Allocated to flutter+bronchodilator 
group (n= 7) 
 Received allocated intervention (n= 7) 
 
Analysed immediately (n= 7) 
Analysed  after 20 minutes (n= 7) 
♦ Excluded from analysis (give reasons) (n=0) 
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results. The level of significance set at 0.05.Flutter Exercises
Subjects were seated upright and held the flutter device
with no inclination. The breathing exercises were undertaken
for 30 min using quiet breath in a controlled manner where they
inhaled through the nose and then exhaled through their mouth
with a slow and prolonged expiration. They were instructed to
perform the exercises feeling the vibration in their external
chest wall. They did 1 min of rest every 4 min of flutter and the
flutters were interrupted any time that the subjects wanted to
cough or expectorate sputum. The ‘‘flutter-sham’’ intervention
was used as a control where the flutter device was used without
the stainless steel ball.
Primary Outcome
Impulse Oscillometry
The IOS system (IOS, Jaeger Master Screen, Jaeger Co,
Wurzburg, Germany) noninvasively assesses respiratory
mechanics without patient cooperation using small pressure
oscillations generated at the mouth during spontaneous breath-
ing. During the test, subjects firmly supported their cheeks
while sitting with their neck in a comfortable neutral posture,
wearing a nose clip, and tightly sealed their lips around the
mouthpiece in order to stabilize the position of their tongue and
to avoid buccal air leaks. Whole-breath, inspiratory (insp), and
expiratory (exp) IOS measures of resistance and reactance were
measured at an oscillation frequency of 5 and 20Hz (R5, X5,
R20, X20), frequency dependence of resistance and reactance
from 5 to 20Hz (R5–20, X5–20), Fres, and low-frequency
reactance area (AX; reactance between 5Hz and Fres).
Reported results are the average of 3 technically acceptable
periods of 40 to 60 s of measure.9
Secondary Outcomes
Exhaled Nitric Oxide Measurements
FeNO was measured by a chemiluminescence analyzer
(NIOx-Flex, Aerocrine AB, Solna, Sweden), at an expiratory
flow rate of 50mL/s by applying resistance of 50 cm H2O/mL/
s.13,14 Each subject performed 2 exhalations using a vital
capacity maneuver and the mean of these values was taken.
Spirometry
The FEV1 and FVC were measured using a dry wedge
spirometer (Jaeger Co,Wurzburg, Germany). Baseline values at
each visit were measured after at least 15 min of quiet rest, and
the results (absolute values and percent predicted) are reported
as the highest of the 3 readings made at 1 min intervals.
Cough and Secretions
The number of spontaneously reported cough episodeswere
recorded and the expectorated secretion volume during each
intervention was collected, weighed, and classified with a puru-
lence score based on a previously described numerical visual
scale, which ranges from 1 (mucoid) to 5 (yellow/green).15
Data Analysis
The patients were randomized by a computer program and
the sample size was calculated 14 patients based on R5 values
from a previous paper,8 where there is a mean difference of
Medicine  Volume 94, Number 42, October 20150.08, a standard deviation of 0.07, a power of 90% and a¼5%.
Results were compared: (a) immediately after to baseline
values, (b) after 20 min of rest to baseline values, and (c) after
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.20 min of rest to values immediately after using Friedman’s test
followed by Dunn’s multiple comparison test; paired t test was
used for comparisons before and after FeNO and spirometry
Oscillation on Airway ResistanceEffect size was used to calculate responsiveness and
classified as small (0.2), moderate (0.5), or large (0.8).
RESULTS
There were no differences between baseline values ondifferent study days in the COPD. All subjects remained stable
before and after interventions, with normal values of heart rate
and oxygen saturation levels.
Impulse Oscillometry
Flutter: X5insp became more negative (greater magni-
tude) immediately after the flutter exercises when compared to
baseline values (P< 0.05) suggesting increasing distal airways
airflow limitation and this regional airways effect was also
supported by an increase (shift to the right) in Fres. However, no
significant differences were observed in measures of R immedi-
ately after the flutter exercises (Table 1, Figs. 2 and 3)
suggesting that X5 was more sensitive than R5 to assess distal
airway mechanics.
Following 20 min of rest, a significant decrease in
measures of distal IOS R5 (whole-breath, inspiratory and
expiratory phases, DR5), R5–20, AX, and central airway
resistance-R20 was observed in values compared to those taken
just after the flutter exercises, implying that after a period of rest
there was an attenuation in the distal airflow limitation (detected
by X5insp) and an improvement in airflow limitation through-
out the central and distal airways; that is the initial peripheral
airways disturbance had not spread to the central airways.
X5exp was also significantly (P< 0.05) decreased (Table 1,
Fig. 3).
When comparing values after 20 min of rest to baseline
values, only R5 achieved lower values (P< 0.05) (Table 1,
Fig. 2) implying an improvement in distal airflow limitation
compared to baseline.
The effect size was 0.44 for R5, 0.54 forDR5, 0.83 for R5–
20, 0.90 for X5insp, 0.69 for Ax, and 0.47 for Fres. For the other
parameters the effect size ranged from 0.12 to 0.389.
Flutterı¨þı¨bronchodilator: there were no significant
changes (worsening) in R or X immediately after flutter exer-
cises compared to baseline (Table 1, Fig.s 2 and 3), implying
that prebronchodilator prevented the distal (X5insp) airflow
limitation that was observed with the flutter exercises alone.
Following 20 min of rest, a decrease in the distal-R5
(whole-breath, inspiratory and expiratory phases, DR5), R5–
20, and also central-R20, was observed compared to those taken
just after the flutter exercises, implying that prebronchodilator
improved airflow limitation throughout the central and distal
airways. However, there was a decrease in the distal airway
reactance-X5insp values implying that the bronchodilator pre-
vented the early decrease in X5insp observed with flutter
exercises alone.
When comparing values following 20 min of rest after the
flutter exercises to baseline values, the whole breath R5
decrease, observed with flutter exercises alone, was still sig-
nificantly present even after prebronchodilator (P< 0.05)
(Table 1, Fig.s 2 and 3), implying an improvement in the distal
airflow limitation that was not altered with prebronchodilator.
Additionally, distal IOS measures of R5 (whole-breath,
www.md-journal.com | 3
TABLE 1. IOS Measurements in COPD Patients Using Flutter and FlutterþBronchodilator
Flutter FlutterþBronchodilator
Before After
After 20 , min




hole breath 0.63 0.16 0.68 0.21 0.61 0.18 b c 0.61 0.28 0.63 0.26 0.56 0.24 b c
inspiratory 0.52 0.12 0.54 0.14 0.50 0.11 c 0.46 0.16 0.49 0.16 0.45 0.15 c
expiratory 0.73 0.21 0.81 0.30 0.70 0.25 c 0.72 0.36 0.75 0.36 0.65 0.32 b c
D R5 -0.22 0.13 -0.27 0.19 -0.20 0.16 c -0.26 0.21 -0.26 0.22 -0.20 0.18 b c
R20 (kPa/L/s) 0.42 0.12 0.43 0.14 0.41 0.15 c 0.41 0.15 0.42 0.16 0.39 0.14 b c
R5–20 (kPa/L/s) 0.21 0.08 0.25 0.10 0.20 0.06 c 0.20 0.15 0.21 0.12 0.18 025 c
X5 (kPa/L/s)
whole breath -0.27 0.10 -0.28 0.11 -0.26 0.10 - -0.27 0.15 -0.25 0.11 -0.25 0.12 -
inspiratory -0.21 0.05 -0.33 0.20 -0.24 0.09 a -0.19 0.06 -0.23 0.23 -0.19 0.05 b
expiratory -0.34 0.18 -0.39 0.20 -0.34 0.17 c -0.38 0.33 -0.44 0.29 -0.37 0.29 -
D X5 -0.13 0.17 -0.06 0.20 -0.10 0.16 - -0.19 0.30 -0.20 0.26 -0.18 0.26 -
Ax (kPa/L) 2.47 1.23 3.07 1.66 2.31 1.10 c 2.38 2.53 2.23 1.90 2.10 2.10 -
Fres (Hz) 24.95 4.03 26.15 4.78 24.24 4.29 a 22.54 7.70 23.49 6.14 21.85 7.01 -
Values are meanSD. Ax¼ reactance area, COPD¼ chronic obstructive pulmonary disease, Fres¼ resonant frequency, IOS¼ impulse oscillo-
metry, R5¼ resistance at 5Hz, R20¼ resistance at 20Hz, X5¼ reactance at 5Hz. Significance (P< 0.05) is given as (a) after flutter exercises to
line
Gastaldi et al Medicine  Volume 94, Number 42, October 2015expiratory phase, DR5), and X5insp, together with central-R20
values were also lower (P< 0.05) (Table 1, Figs. 2 and 3).
baseline values, (b) after 20 min of rest following flutter exercises to base
after flutter exercises.The effect size was 0.46 for DR5, 0.50 for R5–20, 0.40 for
X5, 0.80 for X5insp, 0.41 for X5exp, and 0.41 for Fres. For the































































Before: baseline; aer: immediately aer; aer 20min: 20 minutes ae
R5: resistance at 5Hz; R20: resistance at 20 Hz; X5: reactance at 5Hz; Ax
FIGURE 2. Respiratory system resistance, reactance, and resonant
bronchodilator. COPD¼ chronic obstructive pulmonary disease.
4 | www.md-journal.comFlutter-sham: there were no significant differences before
and after sham intervention in any of the IOS measures for
values, and (c) after 20 min of rest following flutter exercises to valuesCOPD patients. Mean values before and after intervention were
for R5 (0.58 0.15 and 0.60 0.22 kPa/L/s) and X5



































r ; COPD: chronic obstrucve pulmonary disease;  
: reactance area; Fres: resonant frequency. 
frequency from COPD patients using flutter and flutter plus





























































































Before: baseline; aer: immediately aer; aer 20min: 20 minutes aer ; COPD: chronic obstrucve pulmonary disease;  
R5: resistance at 5Hz; X5: reactance at 5Hz; insp: inspiratory; exp: expiratory; ∆R5 or X5: diﬀerence between exp and insp. 
pira
se.
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In COPD patients, compared to baseline values (shown as
the first value in the parentheses), there were no significant
differences in COPD patients immediately after (i) flutter
exercises (40.5 29.9 and 39.3 33.7 ppb), (ii) flutter exerci-
FIGURE 3. Respiratory system resistance and reactance during ins
plus bronchodilator. COPD¼ chronic obstructive pulmonary diseasesþ pretreatment with bronchodilator (32.3 29.4 and
31.7 32.0 ppb), and (iii) after flutter-sham intervention
(44.4 33.7 and 43.6 33.2 ppb) for FeNO.
Spirometry
There were no significant differences compared to baseline
values immediately after flutter exercises, flutter exercisesþ -
bronchodilator, or after flutter-sham intervention (Table 2).
DISCUSSION
We evaluated the acute effects of intrathoracic oscillation
using breathing exercises through a flutter device in patien
TABLE 2. Spirometry Measurements in Healthy Subjects and COPD Patients Using Flutter-Sham, Flutter Exercises, an
FlutterþBronchodilator
Flutter-Sham Flutter Exercises FlutterþBronchodilator
Before After Before After Before After
COPD FVC (%) 109.8 19.6 109.0 17.5 109.4 18.4 107.3 18.1 105.8 16.2 102.1 18
FEV1 (%) 67.0 17.3 65.3 14.6 67.6 17.7 66.0 15.5 62.1 16.7 60.3 17.
FEV1/FVC 50.3 12.0 49.7 10.8 51.0 13.0 51.0 12.5 48.5 12.8 48.9 12.
MEF25–75 (%) 17.8 6.8 17.6 6.9 18.93 8.0 18.0 7.1 15.7 6.4 15.1 7.0
Values are meanSD. COPD¼ chronic obstructive pulmonary disease, FVC¼ forced vital capacity, FEV1¼ forced expiratory volume in 1
IOS¼ impulse oscillometry, MEF¼medium expiratory flow.
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The COPD patients had significantly greater volumes of
secretions with the flutter exercises (2.54 1.39 g) compared to
the flutter-sham intervention (1.5 1.33 g) (P< 0.05). There
were also more spontaneous coughs recorded in the COPD
patients during flutter exercise and flutterþ bronchodilator
(3.95 and 3.63 coughs, respectively) than during flutter-sham
intervention (1.69 coughs). There were no differences among
purulence score (sham: 2.57 0.79; flutter: 2.30 0.82; flut-
terþ bronchodilator: 2.60 1.34).








with COPD and observed this common physiotherapeutic inter-
vention led to a perturbation of small airway respiratory
mechanics with temporary worsening of IOS markers of distal
lung airflow limitation identified by a significantly decreased
inspiratory reactance (X5insp) and increased resonant fre-
quency (Fres). These findings were supported by a larger
Ax, R5insp, R5exp, R5-R20 which also signified increased
obstruction, but crucially, contrary to X5insp and Frs did not
reach significant values suggesting that reactance-X5 was a
more sensitive measure than resistance-R5 to assess distal
airway mechanics. After a period of rest of 20 min the most
significant observation was a reduced R5, lower than baseline
for flutter and flutterþ bronchodilator interventions, signifying
the improvement of the airway obstruction following flutter
treatment and at this time point both X5insp and Frs normalized,
suggesting improvement in the distal airflow limitation. How-
ever, the early distal airways worsening observed immediately
post flutter exercises was prevented by pretreatment with a
short-acting bronchodilator, that was followed by an improve-
ment in the central and peripheral airflow limitations after a 20
min period of rest.
According to the effect size calculation it means a mod-
erate effect for the R and X, especially for peripheral airways,
with and without bronchodilator, and it needs to be pointed that
the R5 decreased from 0.61 in the baseline to 0.56 kPa/L/s after
20 min of rest, almost achieving the minimal clinical important
difference (MCID) calculated as 0.55 kPa/L/s (baseline – 0.5
SD).16 This difference is similar to the study of Figueiredo et al8
and higher than ones presented as a bronchodilator
response.17,18
Several studies utilizing body plethysmography have
reported no change in the airways resistance after flutter
exercises in patients with COPD5 and cystic fibrosis,6,7 and
one study has demonstrated a decrease in the total respiratory
system resistance after flutter exercises in patients with bronch-
iectasis and large amounts of secretions.8 Our study is the first to
show a decrease in the respiratory system resistance and
reactance after flutter exercises in COPD patients and our
results suggest that this decrease is independent of the amount
of secretions.
The retention of airway secretions can contribute to an
increase in airway inflammation and resistance and the flutter
device has been demonstrated to be efficacious in the removal
of airway secretions. Several investigators have studied the
effect of flutter intrathoracic oscillations on the viscoelastic
properties of airway mucus in secretions from patients with
cystic fibrosis and bronchiectasis. After 30 min of flutter
oscillation, studies have reported a decrease in the rigidity
factor of mucus samples and mucus viscosity, but no change
in mucociliary transport and cough.19–21 However, after 4
weeks of treatment with flutter there was an increase in the
mucociliary and cough clearance indices and an increase in the
in vitro mucus cough transport.22,23 A Cochrane review con-
cluded that there is no clear evidence whether oscillation was a
more or less effective intervention overall than other forms of
physiotherapy in cystic fibrosis patients.24
The beneficial effects of flutter oscillations on pulmonary
function were observed in patients with cystic fibrosis, bronch-
iectasis, and others comparing the intervention of flutter with
either a control group, a sham group, or other physiotherapy
techniques.25–32 In contrast, other similar studies have not
Gastaldi et aldemonstrated any effect on lung function.5–7,22,33–40 Indeed,
some studies have reported a worsening in the pulmonary
function in cystic fibrosis patients.41,42 In COPD patients,
6 | www.md-journal.cominvestigators have shown an increase in sputum volume but
no change in pulmonary volumes or oxygen saturations after 1
to 2 flutter sessions36,37 and an improvement in the broncho-
dilator response after 1 week.43
We observed a significant decrease in airway resistance
and reactance in COPD patients after flutter exercises and,
although the total amounts of expectorated secretions were
small, our patients had higher volumes of secretion after flutter
than control (<3 g of wet sputum volume on average). Yet the
R5, DR5, and X5 values were significantly decreased after
20min compared to baseline with and without bronchodilator
meaning that there was a decrease in the flow limitation defined
as the absence of increased expiratory flow despite an increase
in driving pressure.10,11 In light of this finding, we consider that
the beneficial effect of flutter exercises on airways resistance
and reactance could be related not only to secretions but also
keeping the airways patent, suggesting that the device could be
prescribed for patients with expiratory flow limitation with or
without secretions.
A transitory increase in the resonant frequency and reac-
tance at expiratory phase observed could be related to more
spontaneous cough and expectorated secretions in our COPD
patients induced by flutter, even though all patients had a 3 min
of rest after cough to perform the test9 because during cough
there is a dynamic compression in the airways in the expiratory
phase that can increase the resistance.10,44
Nicolini and colleagues found a decrease in sputum neu-
trophils and blood C-reactive protein after 15 days use of high-
frequency chest wall extrathoracic oscillation in patients with
bronchiectasis.45 Using FeNO as a noninvasive, simple, and
reproducible test to assess airways inflammation we observed
no changes in FeNO levels after flutter in COPD patients,
probably as they have a chronic inflammation and were sub-
mitted to a single session of treatment or because it may also
reflect oxidative stress in the COPD airways.13,14,46
In our study, spirometry results were not affected by the
flutter exercises in COPD patients, confirming that IOS can be a
more sensitive method to detect changes in airway obstruction
and a good method to study CPT effects.9–12 Reactance was a
sensitive expression of increased narrowing of airways immedi-
ately after flutter exercises and a decrease in the expiratory flow
limitations after 20 min of rest.
STUDY LIMITATIONS
We speculate that the decrease in the respiratory system
resistance and reactance could be related with less breathless-
ness that was referred by some patients and we consider the
absence of some objective measure of dyspnea, well being, or
satisfaction scales, as a main limitation of this study. Addition-
ally, it is important to know if there is a decrease in inflam-
mation and the exacerbation episodes in a long-term study.
CONCLUSIONS
In conclusion, intrathoracic oscillation with oscillating
positive expiratory pressure device (flutter) can decrease air-
ways resistance and reactance and expiratory flow limitation in
COPD patients with and without secretions, and an immediate
increase in the reactance can be prevented by pretreatment with
bronchodilator. IOS measures of reactance were more sensitive
to detect small airways disease than spirometry that was not
Medicine  Volume 94, Number 42, October 2015affected by flutter exercises. The effect of intrathoracic oscil-
lations on airways inflammation needs to be better defined in
future studies.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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